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Collaboration1. Introduction
Familial hypercholesterolaemia (FH) is a common
genetic disorder affecting low-density lipoprotein choles-
terol (LDL-C) metabolism, resulting in reduced catabolism
of LDL particles and marked elevations in circulating LDL-
C [1e4]. If untreated, lifelong exposure to elevated LDL-C
results in the development of atherosclerotic lesions early
in life and a substantially increased risk of premature
cardiovascular disease as compared to the general pop-
ulation [1e6]. In contrast, early detection and effective
treatment of FH can result in a significant improvement in
clinical outcomes [7,8]. Despite these compelling data, FH
remains largely underdiagnosed with less than 5% of
individuals with FH being identified in most regions around
the world [1]. Compounding its burden is the observation
that FH is undertreated even among those with an estab-
lished diagnosis [1,9e11]. Moreover, an increase in the
evidence-based recommendations for the detection and
treatment of patients with FH to reduce cardiovascular risk
are needed: whereas the class of recommendations for FH
in lipid guidelines is high, the grade of evidence still falls
frequently into level C [12].2. Rationale for the EAS FHSC
The reasons behind underascertainment of FH cases are
complex. They include an underappreciation of the true
prevalence of FH. For instance, the prevalence of hetero-
zygous FH (HeFH) was traditionally considered to be
approximately 1:500 individuals [1]. However, in many
cases these figures arose from the extrapolation of a limited
amount of data from selected populations or specific
subgroups to the general population and therefore may be
unreliable [13]. By comparison, contemporary clinical andgenetic studies suggest that HeFH affects approximately
1:200e250 individuals [1,9,14e17], implying that up to
over 30 million individuals could be affected worldwide
[1]. Additionally, the prevalence of FH can vary substan-
tially depending on how FH is defined (i.e. LDL-C
threshold only, mutation definition only, both, or clinical
score composed of several factors) [17]. Similarly, the
observed undertreatment may in part be due to suboptimal
use of available therapies for reasons that are unclear but
may also include a lack of knowledge about the risks of
sub-optimal therapy, concerns about the safety of available
therapies, a lack of available therapies, or even a paucity of
specialists and established guidelines and standards of care
locally. Whilst lipid lowering therapies such as statins are
potent, the high lifetime burden of risk from LDL-C
elevations means that the impact from any therapeutic
intervention is likely to be modest and significantly
undermined when delays in the detection of FH and initi-
ation of pharmacological therapies occur [1,10,18]. Addi-
tionally, the risk of cardiovascular events may also be
influenced by additional factors not always completely
addressed or recognised, e.g. lipoprotein(a) [19,20].
Underappreciation of the prevalence of FH and the adverse
consequences of current clinical practice has ultimately
resulted in a general lack of health policies aimed specifically
at FH and a lack of awareness and education among health-
care professionals and policy-makers [21]. Efforts to tackle
the global burden of FH have been hindered by a lack of
global cohesion. Firstly, the lack of uniformity among
different initiatives, FH definition and ascertainmentmethods
(e.g. opportunistic/cascade/universal screening; clinical/
genetic diagnosis; different clinical criteria; prior absence of
a unifying WHO “International Classification of Diseases”
code for FH) [1,4,21e26] leads to variability in clinical
practice, makes cross-health systems learning difficult, and
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Secondly, data on FH is held in disparate formats acrossmany
sites/countries, resulting in fragmentation and lack of
harmonised data from different cohorts [21,26]. A lack of
structure and the availability of limited resources have made
it hitherto difficult to integrate these cohorts, preventing
researchers from scaling up current data and failing to achieve
the potential of big data.
The gap in healthcare provision, knowledge and effective
strategies requires a collective effort harnessing the combined
potential of individual cohorts across the globe. For instance,
the potential for global collaborations to inform public health
policy reliably about major non-communicable diseases has
been successfully demonstrated by international consortia
such as the Non-Communicable Diseases consortium or the
Emerging Risk Factors collaboration [27e31]. In this
context, the European Atherosclerosis Society FH Studies
Collaboration (EAS FHSC) is being developed as an ambi-
tious international initiative to gather data derived from FH
focused efforts from investigators worldwide [21]. The
development of this wide collaborative network of investi-
gators from different regions and countries will support an
international large-scale FH registry and improve reliability
of data on current clinical practices and corresponding
outcomes. A strategic data sharing and integration plan will
be implemented to efficiently combine data residing in
different sources and formats, bring disparate data silos
together, and provide for the first time a unified view of these
large combined datasets.
Sharing and pooling the data in a structured systematic
approach will allow us to overcome previous barriers and
limitations to international comparisons across different
cohorts [32e36], such as the heterogeneity, diversity and
complexity of the data and standards used. It will align
international efforts and help reduce redundant research,
avoid duplication of efforts, and reduce costs of research. It
will allow us to assess questions which cannot be addressed in
individual studies, and provide greater precision in answering
these questions than hitherto possible.Moreover, it will unveil
additional findings beyond the original hypotheses tested,
facilitate exploratory approaches due to the large sample size
and generate new hypotheses. It may permit us to detect
previously unobservable effects otherwise undetected in
limited individual studies. Finally, it will increase the preci-
sion of estimates and investigate different patterns, trends and
subgroup effects [32e36]. The diversity of the source of these
data will also help provide unique and hitherto unavailable
insights regarding regional and global variations in clinical
practice, which may in turn be due to overt (e.g. health care
delivery systems and other patient-, socio-economic- or
treatment-related factors) or covert (subtle differences in
population genetics) differences across populations.
Thus, information gained from the EAS FHSC will
eventually help support and strengthen the evidence-baseddecision-making process, overcome existing gaps in the
management of FH, and inform health policies and clinical
guidelines development.
3. EAS FHSC aims
The EAS FHSC is a global initiative of stakeholders
involved in the care of people living with FH that seeks to
empower the medical and global community to seek
changes in their respective countries or organisations to
promote early diagnosis and effective treatment of FH.
Specifically, the EAS FHSC aims to:
- Establish a worldwide, standardised registry of patients
with FH by bringing together regional/national/interna-
tional cohorts and registries with access to FH patients.
This will allow the collaboration to maximise the
exploitation of the data to accurately and reliably inves-
tigate (i) the burden of both homozygous FH (HoFH) and
HeFH, (ii) how FH is detected and managed, (iii) the
clinical consequences of current practice on delivery of
care and outcomes, (iv) the factors that influence optimal
management and LDL-C target attainment in FH.
- Disseminate the information gained from the registry to
an international audience including physicians, other
healthcare professionals, policy-makers and patients’
organizations, to sensitise them to the contemporary
burden of FH, encourage open discussion on FH
management, promoting a uniform evidence-based
standard-of-care, and encourage them to contribute
actively to research.
- Consolidate a network of investigators interested in FH
through which collaborative research and networking
on FH can be conducted on a large-scale.
The EAS FHSC registry has been conceived with a long-
term strategy in mind, in order to increase the follow-up of
patients, including new individuals diagnosed with FH over
time, bringing new cohorts into the registry, and take into
account temporal trends and changes in clinical practice, so
that the findings remain relevant. As such, the project is ex-
pected to evolve over time as it will be further developed and
expanded: we will continuously employ the best data sharing
strategies and optimise the operational protocols based on the
experience of the collaboration, number of participants
included, results from the first waves of data collated,
evolving aims, resources available, and feedback for those
utilizing the data and the feedback from the wider medical
community. The EASFHSCprotocol is shown inAppendix 1.
4. EAS FHSC operational structure (Fig. 1)
The EAS FHSC is in the first instance governed by a panel
of experts on FH who form the Executive Committee that
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(Appendix 2). The Executive Committee represents the core
group for overarching management decisions, driving the
collaboration, obtaining support and funding to ensure
sustainability, and will evaluate the proposals for research,
data mining, and expansion of the EAS FHSC.
The Steering Committee represents the advisory
committee to provide guidance on the project development.
It consists of all those investigators/stakeholders/experts
appointed as EAS FHSC National Lead Investigators/
Country-leads (NLI/CLs) for their respective countries/
regions (Appendix 3). The NLI/CLs act as national leaders
for the EAS FHSC within their respective countries or
regions; as such they coordinate and are responsible for the
identification and collaboration from the individual sites
within their country/region, encouraging participation of
other national physicians and researchers in the collabora-
tion, liaising with relevant societies and patients’ organi-
sations, getting appropriate local approvals and permissions
as needed, and gathering data from the respective region/
country for transfer to the Coordinating Centre.
The Coordinating Centre is based at the Imperial Centre
for Cardiovascular Disease Prevention (ICCP), Imperial
College London (ICL), UK. It acts as the central point for
data collation, management, standardisation, consolidation,
analyses and queries, and it communicates, supports and
coordinates the activities of the investigators involved. The
Coordinating Centre will ensure the computational tools
needed to share, collate and manage the data and will make
use of analytical partners (e.g. informatics, biostatistics) to
ensure the accurate generation of results.Fig. 1. EAS FHSC operationaStakeholders with access to data on FH patients and data
sources are identified through a review (Medline,
EMBASE) of relevant published articles and hand search of
papers and reports, through contact with national/interna-
tional scientific societies, and through face-to-face meet-
ings at major conferences. These investigators are
approached and invited to join to the EAS FHSC as NLI/
CLs after an initial assessment to establish the scope and
characteristics of their data source. This decision is based
on a combination of factors including, but not restricted to:
estimates of the number of FH patients; information
regarding how patients are managed and what key policies/
methods underpinned their management decisions (e.g.
whether cascade screening is carried out, whether genetic
testing is available, etc.); capacity and resources available
to lead EAS FHSC-related activities and coordinate other
contributing investigators within their country/region;
willingness to participate and conform to the local and
project data management safeguard. At the time of the
present submission, there were NLI/CLs investigators
formally involved from over 50 countries worldwide
(Fig. 2), including those coming directly to the EAS FHSC
and from partnerships between the EAS FHSC and other
related initiatives, i.e. the 10 Countries Study and the
ScreenPro FH programme (Appendix 3).
5. EAS FHSC methodology
Data from multiple cohorts, registries, databases and
collections with access to information on individuals with
a clinical and/or genetic diagnosis of HoFH or HeFH willl/governance structure.
Fig. 2. Countries with investigators formally involved in the EAS FHSC (updated at the time of the present submission) Map created with mapchart.net.
Fig. 3. Data workflow and FH Data Warehouse. (A) Individual investigators from each local site will contribute to the FH registry through the National Lead
Investigators/Country-leads (NLI/CLs) for each region or country. These NLI/CLs will transfer and upload the data to the Coordinating Centre through
a bespoke secure web portal. (B) The FH Data Warehouse will be a complete platform supporting various research activities and thus will be composed of the
following components: Web Portal for Data Collection; Data Validation; Data Collation; Data Analysis Tools; Web Portal for Reporting; Data Storage;
Privacy Tool; Data Management Workflow; Workflow Monitoring; Logging Tool. (C)Multi Stage Data Storage for enhanced Security: Data Extraction; Web
Portal for Data Collection; Temporary Data Server for Data Storage; Intermediary Data Server for Data Harmonisation; Secure Data Server for Data
Warehouse; Application Server for Data Analysis and Reports. See Appendix 1 for a detailed description.
6 A.J. Vallejo-Vaz et al. / Atherosclerosis Supplements 22 (2016) 1e32
7A.J. Vallejo-Vaz et al. / Atherosclerosis Supplements 22 (2016) 1e32be merged and harmonised into the global EAS FHSC
registry. Investigators from the local sites will contribute to
the FH registry through the NLI/CLs for the corresponding
region or country. The latter will transfer and upload the
data to the Coordinating Centre to be incorporated into the
FH registry (Fig. 3A).
In order for the investigators to provide reliable data for
inclusion into the registry, a set of minimum predefined
quality and operational criteria have been laid out (Table 1),
which must be satisfied by individual contributing cohorts.
A minimum set of data (core data) are required for inclu-
sion in the registry, comprising general and demographic
information, familial and personal cardiovascular history,
FH diagnostic criteria, lipid-lowering medication with
doses, laboratory lipid profile, and clinical outcomes if
follow-up data are available (retrospective or prospective).
Where genetic tests are available, these genetic data form
part of the core data requested; in case of HoFH, data about
LDL-aphaeresis are also collected. Additionally, where
available, a number of other parameters of interest will beTable 1
EAS FHSC Registry: predefined quality and operational criteria for
inclusion/exclusion of data to be shared.
(i) The data must be in electronic format.
(ii) The amount of data shared should be considered enough to
add relevant information to the registry.
(iii) The data must have been collected rigorously following a
standardised well-designed protocol; inclusion and
exclusion criteria must be well defined; FH must be well
defined according to accepted criteria and not rely only on
self-reported history of FH; any measurements recorded
must have been done with validated and standardised
methods and devices; standardised definitions should have
been used; the data source/participants included should be
representative of the target population.
(iv) The parameters recorded must include at least the
minimum set of data (core information) as specified in the
protocol.
(v) Local ethical and security aspects must be in place; a data
sharing agreement must be signed prior to any data
transfer.
(vi) Data must conform with the inclusion/exclusion criteria:
Inclusion
criteria
(i) Individuals with a diagnosis of heterozygous or
homozygous FH.
- Diagnosis: clinical and/or genetic.
- Also including positive clinical diagnosis with negative
genetic test and vice versa.
- In case of clinical diagnosis:
- Criteria used: Dutch Lipid Clinics Network, MedPed,
Simon-Broome, Japanese criteria, or other to be
specified.
- Categories of possible, probable and confirmed FH.
(ii) Relatives of index cases without a diagnosis of FH
where screening (cascade or other) is carried out.
Exclusion
criteria
- Secondary causes of dyslipidaemia (e.g. untreated
hypothyroidism, cholestasis, nephrotic syndrome).
- Where data collation does not conform to the local or
country wide standards for anonymised data.collected (Appendix 1). Where possible, standardised field
definitions will be used and free entry text avoided. Our
main long-term outcomes of interest will include all-cause
and cardiovascular mortality and fatal/non-fatal cardiovas-
cular events. Nevertheless, given the unique nature of the
EAS FHSC database, information on factors such as statin
intolerance, incident diabetes, aortic valve/supravalvular
disease or cancer will be also sought and analysed. Updates
of the shared datasets will be encouraged to be provided
within a reasonable time-frame.
For each cohort/dataset a two-stage approach is fol-
lowed: the first step comprises the collation of the cross-
sectional and retrospective data readily available; the
second stage involves the integration of longitudinal,
prospective records and follow-up.5.1. Data managementManagement of this large volume of data securely will
require the development of an informatics platform, which
requires various steps from designing data models, collec-
tion, validation, harmonisation, transformation and analysis
and reporting.
In the first instance, a secure web portal will be devel-
oped for the datasets to be transferred to the Coordinating
Centre to provide an automated solution for data transfer,
visualization and coordination. Data sharing plans involve
instructions to the lead investigators for data to be trans-
ferred and data to be collected, updated with feedback for
the individual investigators providing the data.
The preliminary data shared will be checked for
consistency and accuracy by at least 2 independent inves-
tigators of the Coordinating Centre (scientific coordinator,
data manager) and any discrepancies will be resolved by
raising queries with the individual investigators. After
ensuring satisfactory data quality, the information will be
saved and harmonised into a bespoke central database (FH
Data Warehouse [FHDW]) securely hosted on a university
server by the Coordinating Centre, in strict adherence with
all data safety protocols and regulatory requirements. The
Coordinating Centre, supported by a technical team, will
develop cutting edge and artificially intelligent routines
incorporating machine learning for automated data clean-
ing, harmonising and make the data uniform and compat-
ible. The data architecture and platform will support secure
incorporation of data irrespective of source or format from
multiple global repositories/databases/file systems allow-
ing: data cleaning, validation, quality control and merging
into the FHDW; retrospective and ongoing prospective data
pooling, harmonisation and analysis. Regular monitoring of
various stages of data flow will ensure that appropriate
quality standards are maintained and that any deviations
from protocols are immediately reported and rectified. The
resource will make use of existing standards for wider user
acceptance, technical interoperability and scalability.
Regular surveys of the users’ (i.e. lead investigators’)
Table 2
EAS FHSC scientific research questions.
The EAS FHSC aims to establish an international registry of studies on FH
with a view to better quantifying more reliably than hitherto possible:
1 How FH patients are detected, comparison of different proposed
diagnostic criteria, whether current screening strategies for FH are
adequate and, if not, what could be done differently to maximise
coverage.
2 How patients are managed, treatments offered/advised, how their
efficacy is monitored.
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suggestions and feedback, allowing appropriate adaptation
and improvements of the user/resource interface, enhancing
end-user experience for ease-of-use and efficient data
management, allowing the resource to properly grow and
evolve.
The overall structure of the FHDW and platform is
shown in Fig. 3B/C. A detailed description is reported in
Appendix 1 (protocol).3 What proportion of FH patients meet the targets (e.g. LDL-C goals,
patients receiving therapy), the impediments in attaining LDL-C goals,
the role played by societal factors (such as access to healthcare in
different settings and the availability of specialist advice) in enabling5.2. Analysis plan
treatment to achieve LDL-C goal, the influence of geneedrug
interactions in attaining LDL-C goals.
4 Long-term risk of outcomes in patients with FH (including, where
possible, estimates of the years lost due to FH), with a special focus on
the following end-points:
- Primary end-point 1: the composite of Cardiovascular Disease Events
(fatal and non-fatal).
- Primary end-point 2: Cardiovascular mortality.
- Primary end-point 3: All-cause mortality.
- Secondary end-points:
- Each component of the Cardiovascular Disease Events end-point
separately.
- Aortic valve and supravalvular disease.
- Statin intolerance (clinical, biochemical).
- New onset of diabetes.
- Cancer diseases.
- Pregnancy outcome in female patients with FH.
5 To establish the value of incorporating genetic data and other factors
(e.g. lipoprotein[a]) into the clinical diagnosis of FH and estimation of
the risk of outcomes.
6 The impact of patient-specific factors, socio-economic factors and
treatment-related factors on LDL-C goal attainment and cardiovascular
risk.
7 Potential variations depending on different geographic settings as a
result of factors such as population genetics, health care delivery systems
and other patient-, socio-economic- or treatment-related factors.
8 Where possible, evidence for economic evaluation of different screening
strategies and of interventions will be addressed.
The following definitions shall apply: (i) Cardiovascular disease events:
the composite of fatal and non-fatal coronary heart disease/acute coronary
syndrome/myocardial infarction, cardiac sudden death, fatal and non-fatal
stroke, transient ischaemic attack, peripheral vascular disease, and revas-
cularization (percutaneous or surgical); (ii) Aortic valve disease: confirmed
by any imaging test; (iii) Statin intolerance (clinical and/or biochemical):
defined according to the EAS consensus panel [37]; (iv) New onset of
diabetes mellitus: fasting glycaemia >126 mg/dL at least in two separate
occasions, glycosylated haemoglobin 6.5% (48 mmol/mol), and/or
patient receiving a new prescription of an antidiabetic drug [38].After ensuring consistency and compatibility of the
information and description of the variables, the data from
various providers will be merged and analysed at an indi-
vidual level as a composite dataset. Where this is not
possible, analyses will be undertaken at a country/provider
level, by analysing each dataset individually and then
pooling the results together.
We will conduct different types of analyses, such as
assessing the validity of previous published findings with
greater power and precision, conducting alternative anal-
yses of the same data, cross-cohort comparisons, analysing
unpublished data (not previously conducted due to low
sample size within each separate dataset), conducting
exploratory analyses to generate new research hypotheses,
etc.
We will analyse the data to address a number of
research questions as shown in Table 2 [37,38]. Standard
validated statistical procedures and models for observa-
tional studies and weighted meta-analyses (individual
participant data meta-analysis where possible; meta-
analysis of aggregated data alternatively) will be
applied. Statistical methods described in studies such as
the Emerging Risk Factors Collaboration [39,40] or the
Non-Communicable Diseases Risk Factor Collaboration
[27] will be used where appropriate. After exploratory
analyses with description of the variables of interest,
cross-sectional analyses and correlates will be performed.
Comparisons of continuous parameters will be done with
parametric and non-parametric tests as appropriate and
categorical variables using Chi-squared test. We will
quantify various exposure-outcome associations (unad-
justed and adjusted) and epidemiological interactions
using standard regression models. Risk prediction models
using measures of discrimination (concordance index [C-
index], discrimination measure [D-measure]) and reclas-
sification (net reclassification index [NRI]) are intended to
be performed. Cox proportional hazards regression models
stratified by certain variables of interest (e.g. by gender,
country, etc.) and KaplaneMeier estimates of survival will
be generated where time-to-event data is available.Measures of heterogeneity and risk of bias (e.g. regression
dilution over time) will be applied.
We will account for different variables of interest,
carry out appropriate adjustments systematically for
potential confounders, consider key subgroups and correct
for differences in definitions. Where feasible, reliable,
9A.J. Vallejo-Vaz et al. / Atherosclerosis Supplements 22 (2016) 1e32and data available we will also try to roughly approximate
the prevalence of FH by extrapolating the data to the
general population. The different sources of incoming
data will also help assess potential variations depending
on different geographic settings, including factors such as
population genetics, healthcare delivery systems and
other patient-, socio-economic- or treatment-related
factors.
Following a “database-query” model [34], investigators
involved in the registry will be able to submit research
questions they would like to assess through the Coordi-
nating Centre; if the request is deemed to be scientifically
relevant by the Executive Committee and considered
feasible by the Coordinating Centre, the latter will
construct and run the analyses and return the results to the
requester.
6. Ethics, security and regulatory considerations
This project and related research will be conducted in
accordance with the principles of the Declaration of Hel-
sinki. Where required, approval from the corresponding
ethical and/or research committees and informed consent
from participants will be requested by the investigators to
collect, transfer and share the data. Data sharing agree-
ments will be executed between the NLI/CLs sharing the
data and the Coordinating Centre as the recipient of the
data (Appendix 4).
The investigators and the Coordinating Centre will use
all reasonable safeguards in connection with any transfer,
communication or remote access connectivity involving
the data. A secure web portal will be developed as
a means for data entry/coordination and controlled envi-
ronment. Only de-identified, pseudo-anonymised data
will be collected, and removal of identifiers, replacement
of dates with time intervals where possible, and catego-
rization of several characteristics will be performed. A
Global Unique Identifier will be assigned to each subject
enabling investigators to follow their own subjects over
time.
Data servers physically hosted by ICL will be encrypted
to standards utilizing appropriate infrastructure; the data-
base will be configured to be accessed only from approved
terminals/computers. The data storage and handling will be
compliant with the European Data Protection Act.
7. Dissemination and communication
The dissemination and exploitation plan will aim to
maximise the spread of the results within a wide, large and
diverse audience and to make the most of the information
gained from the global FH registry. The means ofdissemination will be varied and tailored to the target
audience, making use of the different resources available
(including eHealth resources) in order to reach and impact
stakeholders involved in the care of FH patients at multiple
levels. The target audience will include physicians and
other healthcare providers, investigators, FH patients and
their relatives through the patients’ organisations, policy-
makers, and, in general, the entire medical community.
As all of these groups are potential users of the information
generated we will aim to reach them all to ensure that the
state-of-the-art information released is utilized to reduce
gaps in knowledge and improve clinical practice for FH
patients. The dissemination plan will include a number of
components, such as publication of results in the form of
reports and scientific articles in peer-reviewed high-impact
international journals; communication of results at major
conferences; academic dissemination; web and social
media dissemination; press releases; engagement with
patients’ organisations; where possible, engagement with
policy-makers/health authorities; networking events
(meetings, web forum).8. Conclusions
The EAS FHSC initiative was formally launched during
the 83rd EAS Congress in March 2015. Since then, a vast
network of collaborators have formally committed them-
selves to join the EAS FHSC initiative; it is expected that
other regions may follow suit as the project evolves,
making the EAS FHSC an internationally leading registry
for FH at the forefront of FH research.
The EAS FHSC initiative represents an excellent
opportunity to integrate efforts across the world to tackle
the global burden of FH. The large, cross-national, robust
information generated from the FH registry will help
narrow gaps in knowledge, inform the medical community
about real-world and best practices, assist in clinical trials
design, and support clinical guidelines and policy devel-
opment. Ultimately, it will help prevent adverse outcomes
and improve care of FH patients.Conflicts of interests
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